The rise and fall of the “minimum clinically important difference”
To access this article, please choose from the options below
FDA device/drug status: not applicable.
Author disclosures: EJC (stock ownership, including options and warrants, Simpirica, Bioassetts, Cytonics; private investments, including venture capital, start-ups, Simpirica; consulting, Medtronic, Synthes, Well-Point B/C B/S; trips/travel, US army; scientific advisory board, Intrinsic Orthopedics, Cytonics; other office, Bioassetts; grants, AO Foundation; fellowship support, DePuy Spine; other relationships, Orthopaedic Surgeon).
PII: S1529-9430(10)00117-8
doi:10.1016/j.spinee.2010.02.013
© 2010 Elsevier Inc. All rights reserved.
